FINWIRES · TerminalLIVE
FINWIRES

$LEGN

5 stories mentioning LEGNUpdated 6d ago

Every FINWIRES story that references LEGN, newest first.

Wire

Legend Biotech's In Vivo CAR-T Cell Therapy Data Validates Approach, RBC Capital Markets Says

Legend Biotech's (LEGN) data from its in vivo CAR-T cell therapy program clearly validates the approach, RBC Capital Markets said in a note Monday.The investment firm said the market is not fully appreciating Legend Biotech's potential with the program, with the company giving back most of its share gains.RBC said the potential for additional follow-up data this year and the fact that in vivo's profile should enable higher peak potential could drive Legend's shares higher.The company could reach the market as soon as 2029 if they move expediently with larger phase 1 dose expansion cohorts, enabling a $3 billion opportunity in non-Hodgkin lymphoma alone, according to the note.RBC Capital Markets retained an outperform rating on the stock, but lowered its price target to $59 from $63.Shares of the company were down more than 14% in Monday trading.Price: $18.97, Change: $-3.26, Percent Change: -14.65%

$LEGN
Wire

Legend Biotech Shares Fall After UBS Downgrade

Legend Biotech (LEGN) shares were down 4.6% in Friday trading after UBS downgraded the company's stock to neutral from buy and adjusted its price target to $28 from $49.Trading volume stood at over 984,600 shares compared with a daily average of 2.6 million.Price: $22.45, Change: $-1.08, Percent Change: -4.59%

$LEGN
Research

UBS Downgrades Legend Biotech to Neutral From Buy, Adjusts Price Target to $28 From $49

Legend Biotech (LEGN) has an average rating of overweight and mean price target of $53.73, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$LEGN
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Interim US-Iran Deal Lifts Risk Sentiment

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4%, and the actively traded Invesco QQQ Trust (QQQ) advanced 1.3% in Thursday's premarket activity, as investors welcomed an interim US-Iran agreement that reduced concerns about disruptions to global energy supplies.US stock futures were also higher, with S&P 500 Index futures up 0.7%, Dow Jones Industrial Average futures advancing 0.3%, and Nasdaq futures gaining 1.3% before the start of regular trading.US initial jobless claims fell to a level of 226,000 in the employment survey week ended June 13 from an upwardly revised 230,000 level in the previous week, compared with expectations for a larger decrease to 225,000 in a survey of analysts compiled by Bloomberg as of 7:30 am ET.The Philadelphia Federal Reserve's monthly manufacturing index rose to 10.3 in June after decreasing to minus 0.4 in May, compared with expectations for a slightly smaller increase to a reading of 10 in a survey compiled by Bloomberg.May's leading indicators data will be released at 10:00 am ET, followed by weekly natural gas stocks at 10:30 am ET.In premarket action, bitcoin was down by 0.6%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.5% lower, Ether ETF (EETH) advanced 0.4%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.4%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.9%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.8% lower.HIVE Digital Technologies (HIVE) shares traded up 12% in early hours activity a day after the company said it received municipal approval to purchase the 32-megawatt Big Boden data center in Sweden from Bodens Utvecklings.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.2%, the Vanguard Health Care Index Fund (VHT) was down 0.1%, while the iShares US Healthcare ETF (IYH) gained 1.1%. The iShares Biotechnology ETF (IBB) was 0.1% higher.Legend Biotech (LEGN) stock was down more than 9% premarket after the company priced an underwritten public offering of 7.7 million American depositary shares at $29.35 each, for gross proceeds of about $226 million.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) gained 2%, and the iShares US Technology ETF (IYW) was flat, while the iShares Expanded Tech Sector ETF (IGM) was up 1.9%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 2.1% higher, while the iShares Semiconductor ETF (SOXX) rose by 4.2%.Intel (INTC) shares were up more than 9% in premarket activity after President Donald Trump said Apple (AAPL) has "agreed to work with Intel to design and build its Chips in America." Apple stock was gaining by 0.3%.EnergyThe iShares US Energy ETF (IYE) gained by 0.03%, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 0.5%.Equinor (EQNR) stock was down more than 3% before market open after edging down 0.2% in the prior close. The company and its partners said they have selected the development concept for the Ringvei Vest project in the Norwegian North Sea, which is expected to contribute about 240 million barrels of oil equivalent.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.3%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was flat, and the iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.5%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) rose 1%.Diageo (DEO) shares gained nearly 1% pre-bell after the Financial Times reported that Chief Executive Dave Lewis has ordered senior executives to implement broad cost-cutting measures as part of a major restructuring effort at the spirits giant.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 1%, while the Vanguard Industrials Index Fund (VIS) was up 1.9% and the iShares US Industrials ETF (IYJ) was inactive.SpaceX (SPCX) stock was down more than 1% before the opening bell after experiencing its first post-IPO retreat from recent record highs, as market data and multiple analysts point to active put option trading and technical downward pressure following the stock's initial surge.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 1.9% to $75.35 per barrel on the New York Mercantile Exchange. Natural gas gained by 0.5% to $3.16 per 1 million British Thermal Units. The United States Oil Fund (USO) declined by 1.2%, while the United States Natural Gas Fund (UNG) was 0.6% lower.Gold futures for July were down by 2.7% to $4,261.40 an ounce on the Comex. Silver futures retreated by 5.6% to $67.33 an ounce. SPDR Gold Shares (GLD) gained by 0.6%, and the iShares Silver Trust (SLV) was 0.02% lower.

Dow JonesNasdaq CompositeS&P 500$AAPL$BETH$BITO$DEO$EEM$EETH$EQNR$EXI$FAS$FAZ$GLD$HIVE$IBB$IGM$IGV$INTC$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$LEGN$PMR$QQQ$RTH$SLV$SOXX$SPCX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Wire

Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says

Legend Biotech (LEGN) reported a solid Q1 for Carvykti, while focus is increasingly shifting to in vivo pipeline programs with potential updates expected in the coming months and additional clinical progress through 2026, RBC Capital Markets said.The brokerage said in a note Tuesday that it was a "strong" quarter for Carvykti with 21% excluding-US and 8% US quarter-over-quarter growth to $597 million, driven by increasing use in earlier lines of therapy, expansion into community treatment centers, and limited competitive pressure.Investor focus is shifting to in vivo CAR-T programs, with the pipeline now including at least three assets targeting GPRC5D, BCMA, and CD19/CD20. The CD19/CD20 program is of particular interest, with an update expected around mid-2026 at a key medical meeting, and given that no abstract was included in the general release, it could potentially be presented as a late breaker in June, the analyst said."We see Carvykti as a best-in-class CAR-T therapy for multiple myeloma," the analyst said, adding that the therapy could reach $2.75 billion in 2026 sales and $8 billion at peak sales.The investment firm sees Legend Biotech on track toward adjusted company-wide profitability in 2026.RBC raised Legend Biotech's price target from $62 to $64, with an outperform rating.Price: $28.78, Change: $+0.52, Percent Change: +1.84%

$LEGN

Track with the FINWIRES app suite